Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APP | P05067 | 1/20 | 0.67 |
| ▸ | MAPT | P10636 | 2/20 | 0.56 |
| ▸ | CA12 | O43570 | 1/20 | 0.46 |
| ▸ | CA1 | P00915 | 1/20 | 0.46 |
| ▸ | CA2 | P00918 | 1/20 | 0.46 |
| ▸ | CA9 | Q16790 | 1/20 | 0.46 |
| ▸ | GRM5 | P41594 | 3/20 | 0.46 |
| ▸ | FFAR1 | O14842 | 4/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 4/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.44 |
| ▸ | NPC1 | O15118 | 3/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | HPGD | P15428 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2114741 | 0.85 | APP (0.92) | APPMAPTCA12CA1CA2 | |
| Diphenylacetylene SCHEMBL960609 | 0.82 | APP (1.00) | APPMAPTCA12CA1CA2 | |
| Diphenylacetylene SCHEMBL29188592 | 0.82 | APP (1.00) | APPMAPTCA12CA1CA2 | |
| Diphenylacetylene SCHEMBL68254 | 0.82 | APP (1.00) | APPMAPTCA12CA1CA2 | |
| Diphenylacetylene SCHEMBL23754282 | 0.78 | APP (0.92) | APPMAPTCA12CA1CA2 | |
| Diphenylacetylene SCHEMBL9273707 | 0.78 | APP (0.92) | APPMAPTCA12CA1CA2 | |
| Diphenylacetylene SCHEMBL28768551 | 0.78 | APP (0.92) | APPMAPTCA12CA1CA2 | |
| Diphenylacetylene SCHEMBL28966277 | 0.78 | APP (0.92) | APPMAPTCA12CA1CA2 | |
| Diphenylacetylene SCHEMBL31243352 | 0.78 | APP (0.92) | APPMAPTCA12CA1CA2 | |
| Diphenylacetylene SCHEMBL5576302 | 0.78 | APP (0.92) | APPMAPTCA12CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108383934-B | Preparation and application method of spiral chiral all-cis poly 3, 5-dihydroxymethyl-4-substituted phenylacetylene derivative without chiral atoms | 哈尔滨工程大学 | 2020-04-07 | — | — | CN | disclosed |
| EP-2592130-B1 | PHOTOCHROMIC MATERIAL | MITSUBISHI GAS CHEMICAL CO (JP) | 2015-01-21 | — | — | EP | disclosed |
| US-8748629-B2 | Photochromic material | MITSUBISHI GAS CHEMICAL COMPANY, INC. (JP) | 2014-06-10 | — | — | US | disclosed |
| EP-2592130-A1 | PHOTOCHROMIC MATERIAL | Mitsubishi Gas Chemical Company, Inc. (JP) | 2013-05-15 | — | — | EP | disclosed |
| US-20130102775-A1 | PHOTOCHROMIC MATERIAL | MITSUBISHI GAS CHEMICAL COMPANY, INC. (JP) | 2013-04-25 | — | — | US | disclosed |
| US-7465755-B2 | Hydrazide derivatives as prostaglandin receptors modulators | LABORATOIRES SERONO SA (CH) | 2008-12-16 | — | — | US | disclosed |
| US-20070185191-A1 | Hydrazide derivatives as prostaglandin receptors modulators | APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (NL) | 2007-08-09 | — | — | US | disclosed |
| EP-1654219-A2 | HYDRAZIDE DERIVATIVES AS PROSTAGLANDIN RECEPTORS MODULATORS | Applied Research Systems ARS Holding N.V. (AN) | 2006-05-10 | — | — | EP | disclosed |
| WO-2005012232-A2 | HYDRAZIDE DERIVATIVES AS PROSTAGLANDIN RECEPTORS MODULATORS | APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (NL) | 2005-02-10 | — | — | WO | disclosed |
| US-20040110665-A1 | Desleucyl glycopeptide antibiotics and methods of making same | KAHNE DANIEL (US) | 2004-06-10 | — | — | US | disclosed |
| US-6699836-B2 | Vancomycin analogs | THE TRUSTEES OF PRINCETON UNIVERSITY | 2004-03-02 | — | — | US | disclosed |
| EP-0667353-B1 | Glycopeptide antibiotic derivatives | LILLY CO ELI (US) | 2003-10-29 | — | — | EP | disclosed |
| EP-1016670-B1 | Glycopeptide antibiotic derivatives | LILLY CO ELI (US) | 2003-09-03 | — | — | EP | disclosed |
| US-6518243-B1 | Desleucyl glycopeptide antibiotics and methods of making same | TRUSTEES OF PRINCETON UNIVERSITY | 2003-02-11 | — | — | US | disclosed |
| US-20020042365-A1 | Vancomycin analogs | TRUSTEES OF PRINCETON UNIVERSITY, THE | 2002-04-11 | — | — | US | disclosed |
| EP-1016670-A1 | Glycopeptide antibiotic derivatives | ELI LILLY AND COMPANY (US) | 2000-07-05 | — | — | EP | disclosed |
| US-5977062-A | ACTIVE AGAINST ANTIBIOTIC RESISTANT BACTERIA | ELI LILLY AND COMPANY (US) | 1999-11-02 | — | — | US | disclosed |
| US-5840684-A | Glycopeptide antibiotic derivatives | ELI LILLY AND COMPANY (US) | 1998-11-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040110665-A1 | Desleucyl glycopeptide antibiotics and methods of making same | FUT6, FUT5, ST6GAL1 | APP 3274/4885MAPT 4049/4885CA12 1364/4885 |
| US-20020042365-A1 | Vancomycin analogs | VNN1, PTMS, ASNS | APP 4524/4885MAPT 4344/4885CA12 1118/4885 |
| US-20070185191-A1 | Hydrazide derivatives as prostaglandin receptors modulators | PTGIR, HPGDS, PGF | APP 3789/4885MAPT 4532/4885CA12 4072/4885 |
| US-20130102775-A1 | PHOTOCHROMIC MATERIAL | RB1, BRD4, H1-4 | APP 4330/4885MAPT 3697/4885CA12 3377/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.